Key Points
- CEO Paul Elliot Mann sold 83,758 shares of ASP Isotopes on June 2 at an average price of $8.29, totaling about $694,354. The sale was disclosed to the SEC and was tied to tax withholding from vesting equity awards.
- Mann also sold another 83,759 shares on June 3 at an average price of $7.76, for roughly $649,970, adding to the recent insider selling activity.
- ASP Isotopes stock was down 9.4% and last traded at $7.55, even as the company recently reported a smaller-than-expected quarterly loss and revenue above analyst forecasts.
ASP Isotopes Inc. (NASDAQ:ASPI - Get Free Report) CEO Paul Elliot Mann sold 83,759 shares of the stock in a transaction that occurred on Wednesday, June 3rd. The stock was sold at an average price of $7.76, for a total transaction of $649,969.84. Following the completion of the transaction, the chief executive officer owned 9,579,845 shares in the company, valued at $74,339,597.20. This trade represents a 0.87% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.
Paul Elliot Mann also recently made the following trade(s):
- On Tuesday, June 2nd, Paul Elliot Mann sold 83,758 shares of ASP Isotopes stock. The stock was sold at an average price of $8.29, for a total transaction of $694,353.82.
ASP Isotopes Price Performance
Shares of NASDAQ:ASPI opened at $7.55 on Thursday. The firm's 50 day moving average price is $5.44 and its 200-day moving average price is $5.87. ASP Isotopes Inc. has a twelve month low of $3.92 and a twelve month high of $14.49. The company has a quick ratio of 4.37, a current ratio of 4.39 and a debt-to-equity ratio of 0.69. The stock has a market capitalization of $950.55 million, a PE ratio of -3.63 and a beta of 3.42.
ASP Isotopes (NASDAQ:ASPI - Get Free Report) last released its earnings results on Wednesday, May 20th. The company reported ($0.22) EPS for the quarter, topping analysts' consensus estimates of ($0.28) by $0.06. ASP Isotopes had a negative net margin of 644.40% and a negative return on equity of 112.46%. The company had revenue of $8.36 million for the quarter, compared to analysts' expectations of $3.68 million.
Analyst Upgrades and Downgrades
A number of equities research analysts have commented on the stock. Weiss Ratings restated a "sell (d-)" rating on shares of ASP Isotopes in a research note on Friday, March 27th. Canaccord Genuity Group restated a "buy" rating and set a $11.00 target price on shares of ASP Isotopes in a research note on Tuesday, April 14th. Two investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, ASP Isotopes currently has a consensus rating of "Hold" and an average target price of $13.00.
View Our Latest Report on ASPI
Institutional Investors Weigh In On ASP Isotopes
Institutional investors and hedge funds have recently modified their holdings of the stock. State of Wyoming bought a new stake in shares of ASP Isotopes during the first quarter valued at approximately $29,000. Quantbot Technologies LP bought a new stake in shares of ASP Isotopes during the third quarter valued at approximately $34,000. BNP Paribas Financial Markets raised its position in shares of ASP Isotopes by 84.9% during the second quarter. BNP Paribas Financial Markets now owns 5,549 shares of the company's stock valued at $41,000 after buying an additional 2,548 shares during the last quarter. Stephens Inc. AR bought a new stake in shares of ASP Isotopes during the first quarter valued at approximately $44,000. Finally, Broadhurst Jeffrey B bought a new stake in shares of ASP Isotopes during the first quarter valued at approximately $44,000. Institutional investors own 16.80% of the company's stock.
ASP Isotopes Company Profile
(
Get Free Report)
ASP Isotopes Inc, a development stage advanced materials company, focuses on the production, distribution, marketing, and sale of isotopes. It engages in the production and commercialization of Molybdenum-100, a non-radioactive isotope for the medical industry; Carbon-14; and Silicon-28. The company is also developing Quantum Enrichment technology to produce Ytterbium-176, Nickel-64, Lithium 6, Lithium7, and Uranium-235. ASP Isotopes Inc was incorporated in 2021 and is headquartered in Washington, District Of Columbia.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
